drugset / Trial / NCT05939596
A Phase I Clinical Trial to Evaluate the Safety, Tolerability, and Immunogenicity of SARS-CoV-2 Bivalent mRNA Vaccine (LVRNA021)
Phase 1
Unknown
60 enrolled
AIM Vaccine Co., Ltd.
The First Affiliated Hospital of Bengbu Medical University · collab
RandomizedParallel-groupQuadruple-blindPrevention
Summary
This trial is a phase I clinical trial of a SARS-CoV-2 Bivalent mRNA Vaccine (LVRNA021). The trial used a randomized, blinded, placebo-controlled design to evaluate the safety, tolerability, and preliminary immunogenicity of the trial vaccine in participants Aged 18 Years and Older who had received SARS-CoV-2 Vaccine.
Timeline
- Start
- 2023-08-10
- Primary completion
- 2023-09-28
- Completion
- 2024-08-25
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | LVRNA021 | Messenger RNA (mRNA) | 100 ug | Intramuscular |